Category Archives: Biotechnology

Amicus Therapeutics Leads The Way In Rare Disease Technology

The global biotechnological Amicus Therapeutics is at the forefront of cutting-edge therapies to treat rare diseases. The robust pipeline of treatments helps with a long list of genetic disease.

Amicus Therapeutics has a very bold vision. The programs we invest are required to have three characteristics: a rare disease, a devastating disorder and the data must be meaningful to help patients. Our goal is to help patients, caregivers and their families.

Our company believes in the fight and never gives up. We deliver the highest-quality therapies that deliver results. Even in business, we believe building in the long-term. Our results are science-driven. We also promise to offer affordable medicine options for all patients.

Our leadership team is driven toward leading. We do everything we can to inspire the rare disease community. Learn more about Amicus Therapeutics at Seeking Alpha.

Our CEO John F. Crowley is a former Bristol-Meyers-Squibb executive, who became involved in genetic technology after his two children were born with genetic diseases. His bravery is profiled in the movie Extraordinary Measures, starring Brenda Fraser and Harrison Ford. Crowley alone raised over $100 million to find a cure for his children. Visit finance.yahoo.com to know more about Amicus Therapeutics.

Crowley, a U.S. Naval Reserve Officer, graduated from Georgetown University with a degree in foreign service. He also received a Juris Doctorate from Notre Dame University. Crowley also sits on a number of boards including the Family Exemplar Award, the Global Genes Project, the University Council on Science & Technology Award and the Make A Wish Foundation.

Read: https://www.dialdish.com/amicus-therapeutics-fabry-disease/

He continues to lead the way in technological advancements.

The Legend in line with targeted cancer treatments Clay Siegall

Seattle Genetics as per the name has its base in Seattle. It is a biotechnological firm whose specialization is in developing the targeted drugs for the kinds of diseases that have not encountered adequate mortality improvements for long. The success of any company has its roots on the leadership in place. Dr. Clay Siegall is not only the founder but also the CEO of the firm.

He attended The University of Maryland from which he graduated with a Bachelor of Science degree in Zoology. Additionally, he studied his Ph.D. in Genetics at George Washington University.

Since the formation of Seattle Genetics in 1998, Clay Siegall has directed the firm to realize a targeted therapy industry. By developing the first drug conjugate of a FDA-approved antibody, characterized by several approved indications, and enhancing the development of a robust pipeline entailing over twenty drugs. Together with a chain of strategic partnerships with the drug manufacturers such as Bayer, Pfizer, and Genentech.

At the time of establishment, Seattle Genetics was small. However, it is through the leadership of Dr. Siegall that it has grown significantly and currently adequate and qualified researchers regarding the field of cancer research.

Drug varieties keep increasing, and other demands often arise in the area. It is therefore for this reason that Seattle Genetics is prepared to undergo the transformation associated with authority related to drug development in the 21st century.

Clay Siegall believes that systemic chemotherapies, which is the former way of treating cancer, is getting out of use and could be forgotten soon. With the increase in efficacy and value of the targeted therapies over time, Dr. Clay Siegall have the belief that the treatment of the aged is likely to be displaced targeted drugs that are vastly more efficient and increasingly tolerable.

Clay Siegall always had interest in medicine, the technological power and the reason to overcoming diseases, intervening in the course of nature and restoration of health. His interest intensified particularly on cancer treatment in the course of his studies of zoology.

With his increased awareness of other treatments usually entailing amputation and radical surgery, he became convinced that there should be more improved ways.